



Design and synthesis of C₆₀–benzenesulfonamide conjugates

Tatiana Y. Zakharian, David W. Christianson*

Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6323, USA

ARTICLE INFO

Article history:

Received 13 January 2010

Revised 2 May 2010

Accepted 7 May 2010

Available online 12 May 2010

ABSTRACT


Synthesis of C₆₀–benzenesulfonamide conjugates is reported. The strategies for improving their water solubility, as required for binding to human carbonic anhydrase II, are discussed.

© 2010 Elsevier Ltd. All rights reserved.

Since its discovery in 1985,¹ the unique physical properties and chemical reactivity of C₆₀ (fullerene) have led to the exploration of its utility in myriad applications ranging from enzyme inhibitors² to chemical sensors³ to superconductivity.⁴ To date, the use of C₆₀ for biological and medicinal purposes has largely been limited by its poor aqueous solubility, but the development of soluble host–guest encapsulation complexes^{5,6} and covalent derivatization of the C₆₀ scaffolding itself with polar groups⁷ have facilitated the preparation of


aqueous C₆₀ solutions. Importantly, the substituents used to covalently modify C₆₀ not only influence aqueous solubility but also influence and direct biological activity.⁸ Accordingly, C₆₀ derivatives have been utilized in numerous biological applications, for example, as neuroprotective agents,⁹ photosensitizers for photodynamic therapy,¹⁰ MRI contrast agents,¹¹ and transfection agents.¹²

A number of C₆₀ derivatives have been reported to inhibit pharmaceutically important enzymes such as HIV-1 protease¹³ and



Scheme 1. Reagents: (a) toluene, reflux; (b) SOCl₂; (c) pyridine.

* Corresponding author. Tel.: +1 215 898 5714; fax: +1 215 573 2201.
E-mail address: chris@sas.upenn.edu (D.W. Christianson).



Scheme 2. Reagents and conditions: (a) toluene, reflux; (b) Raney Ni/HCOOH; (c) NaBH(OAc)₃, AcOH.

acetylcholinesterase.¹⁴ In these examples, C₆₀ is used as a scaffold to which appropriate functional groups are attached to make specific noncovalent interactions in enzyme active sites based on molecular modeling studies. Remarkably, while molecular models of such protein–fullerene complexes have been described,^{13,15} an X-ray crystal structure determination of a protein–fullerene complex has never been reported.

With an eye toward the ultimate crystal structure determination of a protein–fullerene complex, we now describe the synthesis of C₆₀–benzenesulfonamide conjugates designed to bind to human carbonic anhydrase II (CAII). This zinc metalloenzyme serves as a useful model system for studying protein–ligand interactions.¹⁶ Importantly, CAII contains a cone-shaped active site capable of accommodating C₆₀ tethered to a benzenesulfonamide moiety that confers specificity of binding to the Zn²⁺ ion at the base of the active site; thus, the conjugation of C₆₀ to the benzenesulfonamide moiety is expected to anchor C₆₀ in the enzyme active site. The preparation of C₆₀–benzenesulfonamide conjugates described below represents a series of new chemical entities in the functionalization of C₆₀.

The first C₆₀–sulfonamide conjugate (compound **2**) was obtained by acylation of the previously reported fulleropyrrolidine **1**¹⁷ (Scheme 1), which was handled in dilute solutions to prevent polymerization.

An alternative C₆₀–benzenesulfonamide conjugate (**2**) was prepared by reductive amination of 4-formylbenzenesulfonamide¹⁸ with fulleropyrrolidine **1** (Scheme 2). Reductive amination using NaBH(OAc)₃ has been previously reported as an excellent method to generate N-alkylated fulleropyrrolidines.¹⁹

A C₆₀–benzenesulfonamide conjugate with a longer linker between C₆₀ and the benzenesulfonamide moiety (compound **5**) was prepared by the acylation of aminofullerene **4**²⁰ with 4-aminosulfonylbenzoyl chloride²¹ (Scheme 3).

Treatment of aminofullerene **6**²² with 4-aminosulfonylbenzoyl chloride (Scheme 4) gave a conjugate with a different angle of attachment between the benzenesulfonamide moiety and C₆₀.

The C₆₀–benzenesulfonamide conjugate **3** was insoluble in water-miscible solvents. While all other derivatives **2**, **5**, and **7** were soluble in dimethylsulfoxide (DMSO) and dimethylformamide (DMF), our attempts to produce stable aqueous solutions with organic cosolvent content <50% (vol/vol) failed. Thus, to improve


the aqueous solubility of C₆₀–benzenesulfonamide conjugates, we explored further derivatization of **7** with polar groups.

Direct derivatization of **7** with the protected water-solubilizing groups, generated by the reaction of malonyl chloride with *tert*-butyl 3-hydroxypropionate, was attempted under Bingel conditions²³ but there was no evidence for product formation. To improve the solubility of compound **7** in the nonpolar solvents commonly used for Bingel reactions, the sulfonamide was protected with 2,4-dimethoxybenzyl (DMB) groups.


The new sequence began with compound **10** which itself was available in 3 steps from 2,4-dimethoxybenzylamine and 2,4-dimethoxybenzaldehyde (Scheme 5).

Compound **10** was derivatized with the protected water-solubilizing groups under Bingel conditions to form a mixture of regioisomers (Scheme 6). The sulfonamide and the carboxylic acid-protecting groups were then removed under acidic conditions to yield **11**.


Unfortunately, the solubility of compound **11** in DMSO/water mixtures was only slightly improved in comparison with that of compound **7**. At this stage it became evident that addition of multiple water-solubilizing groups would be desirable. Our efforts along these lines will be reported in due course.




Scheme 3. Reagents and conditions: 4-aminosulfonylbenzoyl chloride, triethylamine (TEA).



Scheme 4. Reagents and conditions: 4-aminosulfonylbenzoyl chloride, TEA.



Scheme 5. Reagents and conditions: (a) $\text{NaBH}(\text{OAc})_3$; (b) 4-(chloro-sulfonyl)benzoic acid, TEA; (c) 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), TEA, aminofullerene **6**.



Scheme 6. Reagents and conditions: (a) 1,3-bis[3-(1,1-dimethylethoxy)-3-oxopropyl]propanedioic acid ester, I_2 , 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); (b) trifluoroacetic acid (TFA)/ CH_2Cl_2 .

Acknowledgment

We thank the American Asthma Foundation for supporting this research.

Supplementary data

Supplementary data associated with this article can be found in the online version, at doi:10.1016/j.tetlet.2010.05.017.

References and notes

- Kroto, H. W.; Heath, J. R.; O'Brien, S. C.; Curl, R. F.; Smalley, R. E. *Nature* **1985**, 318, 162–163.
- Bakry, R.; Vallant, R. M.; Najam-ul-Haq, M.; Rainer, M.; Szabo, Z.; Huck, C. W.; Bonn, G. K. *Int. J. Nanomed.* **2007**, 2, 639–649.
- Amao, Y. *Microchim. Acta* **2003**, 143, 1–12.
- Haddon, R. C.; Hebard, A. F.; Rosseinsky, M. J.; Murphy, D. W.; Duclos, S. J.; Lyons, K. B.; Miller, B.; Rosamilia, J. M.; Fleming, R. M.; Kortan, A. R.; Glarum, S. H.; Makhija, A. V.; Muller, A. J.; Eick, R. H.; Zahurak, S. M.; Tycko, R.; Dabbagh, G.; Thiel, F. A. *Nature* **1991**, 350, 320–322.
- Andersson, T.; Nilsson, K.; Sundahl, M.; Westman, G.; Wennerström, O. *J. Chem. Soc., Chem. Commun.* **1992**, 604–606.
- Atwood, J. L.; Koutsantonis, G. A.; Raston, C. L. *Nature* **1994**, 368, 229–231.
- Wharton, T.; Kini, V. U.; Mortis, R. A.; Wilson, L. J. *Tetrahedron Lett.* **2001**, 42, 5159–5162.
- Da Ros, T.; Prato, M. *Chem. Commun.* **1999**, 663–669.
- Dugan, L. L.; Turetsky, D. M.; Du, C.; Lobner, D.; Wheeler, M.; Almli, C. R.; Shen, C. K.-F.; Luh, T.-Y.; Choi, D. W.; Lin, T.-S. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, 94, 9434–9439.
- Jiang, G.; Zheng, Q.; Yang, D. *J. Appl. Polym. Sci.* **2006**, 99, 2874–2877.
- Toth, E.; Bolskar, R. D.; Borel, A.; Gonzalez, G.; Helm, L.; Merbach, A. E.; Sitharaman, B.; Wilson, L. J. *J. Am. Chem. Soc.* **2005**, 127, 799–805.

12. Nakamura, E.; Isobe, H.; Tomita, N.; Sawamura, M.; Jinno, S.; Okayama, H. *Angew. Chem., Int. Ed.* **2000**, *39*, 4254–4257.
13. Friedman, S. H.; DeCamp, D. L.; Sijbesma, R. P.; Srdanov, G.; Wudl, F.; Kenyon, G. L. *J. Am. Chem. Soc.* **1993**, *115*, 6506–6509.
14. Pastorin, G.; Marchesan, S.; Hoebeke, J.; Da Ros, T.; Ehret-Sabatier, L.; Briand, J.-P.; Prato, M.; Bianco, A. *Org. Biomol. Chem.* **2006**, *4*, 2556–2562.
15. Belgorodsky, B.; Fadeev, L.; Ittah, V.; Benyamini, H.; Zelner, S.; Huppert, D.; Kotlyar, A. B.; Gozin, M. *Bioconjugate Chem.* **2005**, *16*, 1058–1062.
16. Krishnamurthy, V. M.; Kaufman, G. K.; Urbach, A. R.; Gitlin, I.; Gudiksen, K. L.; Weibel, D. B.; Whitesides, G. M. *Chem. Rev.* **2008**, *108*, 946–1051.
17. Borsato, G.; Della Negra, F.; Gasparrini, F.; Misiti, D.; Lucchini, V.; Possamai, G.; Villani, C.; Zambon, A. *J. Org. Chem.* **2004**, *69*, 5785–5788.
18. Van Es, T.; Staskun, B. *Org. Synth.* **1988**, *6*, 631.
19. Xiao, S.; Li, Y.; Li, Y.; Liu, H.; Li, H.; Zhuang, J.; Liu, Y.; Lu, F.; Zhang, D.; Zhu, D. *Tetrahedron Lett.* **2004**, *45*, 3975–3978.
20. Pellarini, F.; Pantarotto, D.; Da Ros, T.; Giangaspero, A.; Tossi, A.; Prato, M. *Org. Lett.* **2001**, *3*, 1845–1848.
21. Hower, J. F.; Henkens, R. W.; Chesnut, D. B. *J. Am. Chem. Soc.* **1971**, *93*, 6665–6671.
22. Zakharian, T. Y.; Seryshev, A.; Sitharaman, B.; Gilbert, B. E.; Knight, V.; Wilson, L. J. *J. Am. Chem. Soc.* **2005**, *127*, 12508–12509.
23. Bingel, C. *Chem. Ber.* **1993**, *126*, 1957–1959.